The current share placement is effectively below the liquidation costs i.e. shareholders equity after assets minus liabilities. Note assets/liabilities may have changed somewhat from last financial year, but the table below does give a rough guide to the value of the company.
That is before considering the products they have, the restructuring they have done to start bringing LDX to profitability, and before considering the expansion of products like the recent FDA approval.
I can't see this staying around 7c for long after the CR is finished and it's all steam ahead for what appears like a company making turnaround of events from FDA approval to higher revenue and better cash flow.
Having started in 2021 and being as high as $1.40, 7c seems like a steal.
The current share placement is effectively below the liquidation...
Add to My Watchlist
What is My Watchlist?
